{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:33:06Z","timestamp":1787682786125,"version":"build-2784847793"},"reference-count":100,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,7,29]]},"DOI":"10.1536\/ihj.23-195","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T22:13:58Z","timestamp":1690582438000},"page":"519-534","source":"Crossref","is-referenced-by-count":12,"title":["Current Diagnosis and Management of Takayasu Arteritis"],"prefix":"10.1536","volume":"64","author":[{"given":"Chandhu","family":"AS","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Danda","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update. Turk J Med Sci 2018; 48: 681-97.","DOI":"10.3906\/sag-1804-136"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 2021; 40: 4391-416.","DOI":"10.1007\/s10067-021-05743-2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Russo RAG, Katsicas MM. Takayasu Arteritis. Front Pediatr. 2018 Sep 24; 6: 265.","DOI":"10.3389\/fped.2018.00265"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Thapa Magar M, Kafle S, Poudel A, Patel P, Cancarevic I. Takayasu&apos;s Arteritis and Its Association With Mycobacterium Tuberculosis: A Systematic Review. Cureus 2021; 13: e16927.","DOI":"10.7759\/cureus.16927"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart 2018; 104: 558-65.","DOI":"10.1136\/heartjnl-2016-310848"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu&apos;s arteriopathy. J Am Coli Cardiol 1988; 12: 964-72.","DOI":"10.1016\/0735-1097(88)90462-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Arend WP, Michel BA, Bloch DA, <i>et al<\/i>. The American College of Rheumatology 1990 criteria for the c1assification of Takayasu&apos;s arteritis. Arthritis Rheum 1990; 33: 1129-34.","DOI":"10.1002\/art.1780330811"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sharma BK, Jain S, Suri S, Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol 1996; 54: S141-7.","DOI":"10.1016\/S0167-5273(96)88783-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kong X, Ma L, Jiangand L. 100.Explore the diagnostic criteria for Takayasu arteritis. Rheumatology 2019; 58: kez058.040.","DOI":"10.1093\/rheumatology\/kez058.040"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Seeliger B, Sznajd J, Robson JC, <i>et al<\/i>. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology 2017; 56: 1154-61.","DOI":"10.1093\/rheumatology\/kex075"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ozen S, Pistorio A, Iusan SM, <i>et al<\/i>. Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR\/PRINTO\/ PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010; 69: 798e806.","DOI":"10.1136\/ard.2009.116657"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Numano F. The story of Takayasu arteritis. Rheumatology (Oxford) 2002; 41: 103e6.","DOI":"10.1093\/rheumatology\/41.1.103"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Goel R, Gribbons KB, Carette S, <i>et al<\/i>. Derivation of an angiographically based classification system in Takayasu&apos;s arteritis: an observational study from India and North America. Rheumatology 2020; 59: 1118-27.","DOI":"10.1093\/rheumatology\/kez421"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology 2014; 53: 793-801.","DOI":"10.1093\/rheumatology\/ket320"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kele\u015fo\u011flu Din\u00e7er AB, K\u0131l\u0131\u00e7 L, Erden A, <i>et al<\/i>. Imaging modalities used in diagnosis and follow-up of patients with Takayasu&apos;s arteritis. Turk J Med Sci 2021; 51: 224-30.","DOI":"10.3906\/sag-2005-70"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dejaco C, Ramiro S, Duftner C, <i>et al<\/i>. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 77: 636-43.","DOI":"10.1136\/annrheumdis-2017-212649"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Matsuyama A, Sakai N, Ishigami M, <i>et al<\/i>. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003; 108: 1469-73.","DOI":"10.1161\/01.CIR.0000090689.69973.B1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu&apos;s arteritis. Rheumatology (Oxford) 2006; 45: 545-8.","DOI":"10.1093\/rheumatology\/kei266"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tombetti E, Di Chio MC, Sartorelli S, <i>et al<\/i>. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther 2014; 16: 479.","DOI":"10.1186\/s13075-014-0479-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wen X, Hou R, Xu K, <i>et al<\/i>. Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis. PLoS One 2021; 16: e0245612.","DOI":"10.1371\/journal.pone.0245612"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nair AM, Goel R, Hindhumati M, <i>et al<\/i>. Serum amyloid A as a marker of disease activity and treatment response in Takayasu arteritis. Rheumatol Int 2017; 37: 1643-9.","DOI":"10.1007\/s00296-017-3786-2"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Savioli B, Abdulahad WH, Brouwer E, Kallenberg CGM, de Souza AWS. Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? Autoimmunity Reviews 2017; 16: 1071-8.","DOI":"10.1016\/j.autrev.2017.07.023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zanwar A, Jain A, Gupta L, <i>et al<\/i>. Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis. Clin Rheumatol 2018; 37: 3439-42.","DOI":"10.1007\/s10067-018-4207-y"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Jain A, Kumar D, Guleria A, <i>et al<\/i>. NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis: Relationship with Disease Activity. J Proteome Res 2018; 17: 3317-24.","DOI":"10.1021\/acs.jproteome.8b00456"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Guilpain P, Mouthon L. Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases. Clin Rev Allergy Immunol 2008; 35: 59-65.","DOI":"10.1007\/s12016-007-8069-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kerr GS, Hallahan CW, Giordano J, <i>et al<\/i>. Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.","DOI":"10.7326\/0003-4819-120-11-199406010-00004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Aydin SZ, Yilmaz N, Akar S, <i>et al<\/i>. Assessment of disease activity and progression in Takayasu&apos;s arteritis with Disease Extent Index-Takayasu. Rheumatology 2010; 49: 1889-93.","DOI":"10.1093\/rheumatology\/keq171"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ureten K, Ozt\u00fcrk MA, Onat AM, <i>et al<\/i>. Takayasu&apos;s arteritis: results of a university hospital of 45 patients in Turkey. Int J Cardiol 2004; 96: 259-64.","DOI":"10.1016\/j.ijcard.2003.07.017"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Misra R, Danda D, Rajappa SM, <i>et al<\/i>. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology 2013; 52: 1795-801.","DOI":"10.1093\/rheumatology\/ket128"},{"key":"30","unstructured":"30. Rajappa S. Outcome of vascular interventions in Takayasu arteritis using the Takayasu arteritis damage score. Arthritis Rheum 2011; 63: 1504."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Grayson PC, Alehashemi S, Bagheri AA, <i>et al<\/i>. <sup>18<\/sup>F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis Rheumatol 2018; 70: 439-49.","DOI":"10.1002\/art.40379"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kang F, Han Q, Zhou X, <i>et al<\/i>. Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu&apos;s arteritis patients. Eur J Nucl Med Mol Imaging 2020; 47: 3107-17.","DOI":"10.1007\/s00259-020-04871-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. van der Geest KSM, Treglia G, Glaudemans AWJM, <i>et al<\/i>. Diagnostic value of [18F]FDG-PET\/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021; 48: 3886-902.","DOI":"10.1007\/s00259-021-05362-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Goel R, Danda D, Joseph G, <i>et al<\/i>. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India. Semin Arthritis Rheum 2018; 47: 718-26.","DOI":"10.1016\/j.semarthrit.2017.09.014"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, <i>et al<\/i>. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79: 19-30.","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Misra DP, Rathore U, Patro P, Agarwal V, Sharma A. Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis. Rheumatol Int 2021; 41: 1729-42.","DOI":"10.1007\/s00296-021-04958-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ohigashi H, Tamura N, Ebana Y, <i>et al<\/i>. Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 2017; 69: 774-8.","DOI":"10.1016\/j.jjcc.2016.07.009"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Padiyar S, Manikuppam P, Kabeerdoss J, Rathore S, Danda D. Update on pregnancy in Takayasu arteritis-A narrative review. Int J Rheum Dis 2021; 24: 758-65.","DOI":"10.1111\/1756-185X.14109"},{"key":"39","unstructured":"39. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu&apos;s arteritis. J Rheumatol 2003; 30: 1793-8."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kleinmann JF, Arnaud L, Sauleau E, <i>et al<\/i>. Efficacy and safety of infliximab originator in patients with Takayasu arteritis within the RTU (temporary recommendation of use) in France. Ann Rheum Dis 2017; 76: 611-2.","DOI":"10.1136\/annrheumdis-2017-eular.1793"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Shinjo SK, Pereira RMR, Tizziani VAP, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007; 26: 1871-5.","DOI":"10.1007\/s10067-007-0596-z"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu&apos;s arteritis. Clin Rheumatol 2010; 29: 329-32.","DOI":"10.1007\/s10067-009-1333-6"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012; 41: 227-30.","DOI":"10.3109\/03009742.2011.633553"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Li J, Yang Y, Zhao J, Li M, Tian X, Zeng X. The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu&apos;s arteritis. Sci Rep 2016; 6: 38687.","DOI":"10.1038\/srep38687"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, <i>et al<\/i>. Leflunomide in Takayasu arteritis - A long term observational study. Rev Bras Reumatol Engl Ed 2016; 56: 371-5 (English, Portuguese).","DOI":"10.1016\/j.rbre.2016.02.003"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sun Y, Ma L, Ma L, <i>et al<\/i>. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu&apos;s arteritis. Rheumatol Int 2017; 37: 2019-26.","DOI":"10.1007\/s00296-017-3847-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Cui X, Dai X, Ma L, <i>et al<\/i>; East China Takayasu Arteritis (ECTA) Collaboration Group. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Semin Arthritis Rheum 2020; 50: 59-65.","DOI":"10.1016\/j.semarthrit.2019.06.009"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Dai X, Cui X, Sun Y, Ma L, Jiang L. Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu&apos;s arteritis: an observational study. Ther Adv Chronic Dis 2020; 11: 2040622320922019.","DOI":"10.1177\/2040622320922019"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Wu C, Sun Y, Cui X, <i>et al<\/i>. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis 2020; 11: 2040622320975233.","DOI":"10.1177\/2040622320975233"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Ying S, Xiaomeng C, Xiaomin D, <i>et al<\/i>. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20930114.","DOI":"10.1177\/1759720X20930114"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Dai D, Wang Y, Jin H, Mao Y, Sun H. The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Int 2017; 37: 1083-8.","DOI":"10.1007\/s00296-017-3704-7"},{"key":"52","unstructured":"52. Quartuccio L, Schiavon F, Zuliani F, <i>et al<\/i>. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu&apos;s arteritis treated with infliximab. Clin Exp Rheumatol 2012; 30: 922-8."},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ujiie H, Sawamura D, Yokota K, <i>et al<\/i>. Pyoderma gangrenosum associated with Takayasu&apos;s arteritis. Clin Exp Dermatol 2004; 29: 357-9.","DOI":"10.1111\/j.1365-2230.2004.01514.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL 2 producing T cells characterize active disease in Takayasu&apos;s arteritis. Clin Immunol 2006; 118: 154-8.","DOI":"10.1016\/j.clim.2005.09.010"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55. Comarmond C, Plaisier E, Dahan K, <i>et al<\/i>. Anti TNF-\u03b1 in refractory Takayasu&apos;s arteritis: Cases series and review of the literature. Autoimmunity Reviews 2012; 11: 678-84.","DOI":"10.1016\/j.autrev.2011.11.025"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Mertz P, Kleinmann JF, Lambert M, <i>et al<\/i>. Infliximab is an effective glucocorticoid sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev 2020; 19: 4.","DOI":"10.1016\/j.autrev.2020.102634"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50: 2296-304.","DOI":"10.1002\/art.20300"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67: 1567-9.","DOI":"10.1136\/ard.2008.093260"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Mekinian A, N\u00e9el A, Sibilia J, <i>et al<\/i>. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012; 51: 882-6.","DOI":"10.1093\/rheumatology\/ker380"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 2012; 64: 1079-83.","DOI":"10.1002\/acr.21636"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Tombetti E, Baldissera E, Franchini S, <i>et al<\/i>. Efficacy of anti-TNF therapy in 15 patients with refractory Takayasu&apos;s arteritis: long term unicentric follow-up. Ann Rheum Dis 2013; 71: 226.","DOI":"10.1136\/annrheumdis-2012-eular.2174"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62. Mekinian A, Comarmond C, Resche-Rigon M, <i>et al<\/i>. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation 2015; 132: 1693-700.","DOI":"10.1161\/CIRCULATIONAHA.114.014321"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Gudbrandsson B, Molberg \u00d8, Palm \u00d8. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 2017; 19: 99.","DOI":"10.1186\/s13075-017-1316-y"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Novikov PI, Smitienko IO, Sokolova MV, <i>et al<\/i>. Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford) 2018; 57: 2101-5.","DOI":"10.1093\/rheumatology\/key197"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Park EH, Lee EY, Lee YJ, <i>et al<\/i>. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int 2018; 38: 2233-42.","DOI":"10.1007\/s00296-018-4159-1"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Banerjee S, Quinn KA, Gribbons KB, <i>et al<\/i>. Effect of treatment on imaging, clinical, and serologic assessments of disease activity in large-vessel vasculitis. J Rheumatol 2020; 47: 99-107.","DOI":"10.3899\/jrheum.181222"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Campochiaro C, Tomelleri A, Sartorelli S, <i>et al<\/i>. Efficacy and safety of infliximab-biosimilar in Takayasu (TAKASIM): a monocentric, observational, prospective, open-label study. Ann Rheum Dis 2020; 79: 1527.","DOI":"10.1136\/annrheumdis-2020-eular.3250"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Campochiaro C, Tomelleri A, Sartorelli S, <i>et al<\/i>. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum 2020; 50: 509-14.","DOI":"10.1016\/j.semarthrit.2020.01.005"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 &apos;difficult-to-treat&apos; cases of Takayasu arteritis. Int J Rheum Dis 2013; 16: 754-61.","DOI":"10.1111\/1756-185X.12220"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013; 40: 2047-51.","DOI":"10.3899\/jrheum.130536"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Novikov P, Smitienko I, Elonakov A, Koilubaeva G, Moiseev S. Safety and efficacy of short-term treatment with tocilizumab in patients with refractory Takayasu arteritis. Ann Rheum Dis 2015; 74: 302.","DOI":"10.1136\/annrheumdis-2015-eular.6048"},{"key":"72","unstructured":"72. Zhou J, Chen Z, Li J, <i>et al<\/i>. The efficacy of tocilizumab for the treatment of Chinese Takayasu&apos;s arteritis. Clin Exp Rheumatol 2017; 35: 171-5."},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Mekinian A, Resche-Rigon M, Comarmond C, <i>et al<\/i>; French Takayasu network. Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun 2018; 91: 55-60.","DOI":"10.1016\/j.jaut.2018.04.002"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Kong XF, Zhang XJ, Lv P, <i>et al<\/i>. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol 2018; 266: 222-8.","DOI":"10.1016\/j.ijcard.2017.12.066"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Shah K, Mason JC. Real life experience of tocilizumab for Takayasu arteritis. Rheumatology (Oxford) 2019; 58: 158.","DOI":"10.1093\/rheumatology\/kez107.086"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Wang T, Liao H. 362. Comparison of efficacy and safety between tocilizumab and cyclophosphamide in treating patients with Takayasu&apos;s arteritis. Rheumatology (Oxford) 2019; 58: 1. kez063.086.","DOI":"10.1093\/rheumatology\/kez063.086"},{"key":"77","unstructured":"77. Kili\u00e7 L, Karada\u011f \u00d6, Erden A, <i>et al<\/i>. Anti-interleukin-6 (Tocilizumab) therapy in takayasu&apos;s arteritis: a real life experience. Turk J Med Sci 2020; 50: 31-6."},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Pan L, Du J, Liu J, <i>et al<\/i>. Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis. Clin Rheumatol 2020; 39: 2369-78.","DOI":"10.1007\/s10067-020-05005-7"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Mekinian A, Saadoun D, Vicaut E, <i>et al<\/i>. Tocilizumab in treatment-naive patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 2020; 22: 7.","DOI":"10.1186\/s13075-020-02311-y"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Prieto-Pena D, Calderon-Goercke M, Bernabeu P, <i>et al<\/i>. Tocilizumab in refractory Takayasu arteritis. open-label national multicenter study of 53 patients of clinical practice. Ann Rheum Dis 2020; 79: 1074-5.","DOI":"10.1136\/annrheumdis-2020-eular.2445"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Isobe M, Maejima Y, Saji M, Tateishi U. Evaluation of tocilizumab for intractable Takayasu arteritis and 18F fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol 2021; 77: 539-44.","DOI":"10.1016\/j.jjcc.2020.12.011"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Nakagomi D, Kronbichler A, Witte T, Mohammad AJ, Jayne DRW. Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology 2018; 57: 1309-10.","DOI":"10.1093\/rheumatology\/kex493"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Pazzola G, Muratore F, Pipitone N, <i>et al<\/i>. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford) 2018; 57: 1151-5.","DOI":"10.1093\/rheumatology\/kex249"},{"key":"84","unstructured":"84. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. Available at: https:\/\/www.clinexprheumatol.org\/abstract.asp?a=9409. Accessed July 17, 2021."},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin 6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.","DOI":"10.1002\/art.23373"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Nakaoka Y, Isobe M, Takei S, <i>et al<\/i>. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018; 77: 348-54.","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"87","doi-asserted-by":"publisher","unstructured":"87. Nakaoka Y, Isobe M, Tanaka Y, <i>et al<\/i>. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology 2020; 59: 2427-34.","DOI":"10.1093\/rheumatology\/kez630"},{"key":"88","unstructured":"88. Prieto-Pe\u00f1a D, Bernabeu P, Vela P, <i>et al<\/i>. Tocilizumab in refractory Caucasian Takayasu&apos;s arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis 2021; 13: 1759720X211020917."},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Terao C, Yoshifuji H, Kimura A, <i>et al<\/i>. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 2013; 93: 289-97.","DOI":"10.1016\/j.ajhg.2013.05.024"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Terao C, Yoshifuji H, Nakajima T, Yukawa N, Matsuda F, Mimori T. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 2016; 45: 80-2.","DOI":"10.3109\/03009742.2015.1060521"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Langford CA, Cuthbertson D, Ytterberg SR, <i>et al<\/i>; Vasculitis Clinical Research Consortium. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 2017; 69: 846-53.","DOI":"10.1002\/art.40037"},{"key":"92","doi-asserted-by":"publisher","unstructured":"92. Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation 2018; 137: 1934-48.","DOI":"10.1161\/CIRCULATIONAHA.117.030423"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Kong X, Sun Y, Dai X, <i>et al<\/i>. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 2022; 81: 117-23.","DOI":"10.1136\/annrheumdis-2021-220832"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Kwon OC, Oh JS, Park MC, <i>et al<\/i>. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 2019; 287: 111-5.","DOI":"10.1016\/j.ijcard.2019.02.046"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Dai XM, Yin MM, Liu Y, Ma LL, Ying J, Jiang LD. Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review. Chin Med J (Engl) 2020; 133: 975-81.","DOI":"10.1097\/CM9.0000000000000704"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis 2020; 79: 1125-6.","DOI":"10.1136\/annrheumdis-2019-216606"},{"key":"97","doi-asserted-by":"publisher","unstructured":"97. Shi G, Hua M, Xu Q, Ren T. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial. Immunobiology 2017; 222: 164-8.","DOI":"10.1016\/j.imbio.2016.10.008"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Shao N, Jia H, Li Y, Li J. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-\u03b1: a randomized placebo-controlled double-blind clinical trial. Immunol Res 2017; 65: 969-74.","DOI":"10.1007\/s12026-017-8917-z"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. de Souza AWS, Machado NP, Pereira VM, <i>et al<\/i>. Antiplatelet Therapy for the Prevention of Arterial Ischemic Events in Takayasu Arteritis. Circ J 2010; 74: 1236-41.","DOI":"10.1253\/circj.CJ-09-0905"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Park HS, Do YS, Park KB, <i>et al<\/i>. Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur J Radiol 2013; 82: 1913-8.","DOI":"10.1016\/j.ejrad.2013.06.019"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/4\/64_23-195\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T04:03:00Z","timestamp":1690603380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/4\/64_23-195\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-195","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"article-number":"23-195"}}